Familial Hypercholesterolemia: A Reportable ACMG Secondary Finding

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. List the 3 common pathogenic variants in FH
2. Recall the inheritance pattern of FH

Estimated time to complete activity: 0.25 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG
President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty: Susan J. Gross, MD, receives consulting fees from Genoox, Inc., and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from Dec 31 2017 through Dec 31 2019, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.2 contact hours.

Read Disclaimer & Fine Print

WHAT IS IT?

Familial Hypercholesterolemia (FH) is a disorder characterized by very high levels of LDL cholesterol (LDL-C) and is the most common inherited cardiovascular disease, with a prevalence of 1:200 to 1:250
- May account for up to 3% of heart attacks in those < 60 years of age
- Prevalence varies among population with high carrier rates in Old Order Amish (1:10) and South Africans of Ashkenazi Jewish (1:67) and Afrikaner descent (1:72-1:100)
Pathogenic variants in 3 genes – LDLR, APOB and PCSK9 – account for 70 to 95% of FH
FH has an autosomal dominant pattern of inheritance with incomplete penetrance
- FH usually refers to the more common ‘heterozygous’ form where only one gene copy has a deleterious mutation
- There is a rare, more severe ‘homozygous’ form of FH where someone inherits two mutated copies of the LDLR gene, one from each parent

NOTE: Because medical interventions can prevent severe morbidity and mortality, Familial Hypercholesterolemia is on the ACMG list of secondary findings. In summary, the ACMG document on reporting such findings makes the following recommendations:

In the course of genetic testing for research or clinical care, the laboratory may identify variants in genes unrelated to the initial indication for testing, but nevertheless may have important health implications
Results of such secondary findings should be communicated to the individuals who may benefit from this knowledge
An individual can ‘opt out’ of receiving secondary findings

KEY CLINICAL POINTS:

Findings may appear in childhood or adulthood
There are formalized diagnostic criteria using clinical and laboratory findings
- Finding a pathogenic mutation in one of the related genes is considered the ‘gold standard’
Appropriate surveillance and treatment can result in good outcomes
Left untreated, there is a 50% chance of a coronary artery event by age 50 in men and 30% risk by age 60 in women
Treatment is multidisciplinary and includes, but is not limited to, specialists in cardiology, lipid management and genetics
- Assess patient and correct for CVD risk factors such as diet, BP, smoking, obesity
- Specialized pharmacotherapy including statins and other lipid reducing medication
- In severe cases, LDL apheresis and liver transplant, although rare, may be required

CLINICAL FINDINGS:

Excessive cholesterol results in the following findings on clinical and radiologic exam

Atherosclerotic plaques in coronary arteries and proximal aorta
Corneal arcus – grey/white ring around the periphery of the cornea, a result of lipid deposit when seen in individuals < 45 years of age (common finding in older people)
Soft tissues
- Tendon xanthomas (Achilles, hands, fingers, knees,elbows)
- Xanthelasma (eyelids)

Credit: Klaus D. Peter, Gummersbach, Germany

MOLECULAR GENETICS & COUNSELING:

What gene/protein is affected and what does it do?

LDLR – Low Density Lipoprotein Receptor: (Most commonly associated with FH) LDLR is the receptor that binds low density lipoproteins (LDLs), the primary cholesterol carrying proteins in the bloodstream
- Reduction or damage to LDL receptors can lead to elevated LDL-C levels
APOB – Apolipoprotein B: APOB is the main apolipoprotein on chylomicrons and LDLs and is important in the functioning of the low-density lipoprotein receptor
PCSK9 – Proprotein Convertase Subtilisin / Kexin type 9: The PCSK9 protein reduces the number of LDL Receptors
- Pathogenic variants result in a ‘gain-of-function’ reducing the number of LDL receptors more than usual, leading to higher LDL-C levels

Inheritance:

FH is an autosomal dominant disorder
It appears that almost all affected individuals will have a parent who is a carrier of a pathogenic variant, meaning the new mutation rate is low

Risks to family members and future offspring:

If a parent of an affected individual carries a mutation, the brothers and sisters of that affected individual have a 50% chance of carrying the mutation
Offspring of affected individuals have a 50% chance of inheriting the mutation and therefore having FH
- Preimplantation genetics and prenatal testing is available